Cencora overview and recent share performance

Cencora (COR) has drawn investor attention after a period of mixed share performance, with the stock showing a 1 day return of 1.03%, a 7 day decline of 4.59%, and a past 3 months decline of 13.46%.

Over a longer horizon, Cencora has a 1 year total return of 7.87%, a 3 year total return that is very large, and a 5 year total return of 1.62x, with the shares last closing at US$308.19.

Recent share price moves have been soft, with the stock showing declines over the past week, quarter, and year to date, even as multi year total shareholder returns remain strong. This signals fading momentum after a solid longer term run.

If Cencora’s recent pullback has you thinking about where else capital could work hard, this is a good moment to scan 33 healthcare AI stocks.

So with Cencora’s recent pullback, solid multiyear total returns, and signs of an intrinsic discount, are you looking at an undervalued healthcare distributor, or a stock where the market has already priced in future growth?

Most Popular Narrative: 23.5% Undervalued

Cencora’s most followed valuation narrative sets fair value at $402.92 per share, well above the last close at $308.19. This frames a sizeable implied discount before you even look at the underlying assumptions.

Cencora's ongoing investment in digital infrastructure and advanced analytics positions the company to capitalize on the accelerating digitization of healthcare and regulatory requirements like the Drug Supply Chain Security Act. These developments may improve supply chain efficiency and transparency, which could support higher net margins and operating income over time.

Want to see what kind of revenue run rate, margin lift, and long term earnings profile this story is built on? The fair value hinges on a specific set of growth assumptions, a richer profit profile, and a future earnings multiple that needs to line up with those forecasts. Curious which of those levers accounts for most of the $402.92 figure?

Result: Fair Value of $402.92 (UNDERVALUED)

However, this hinges on higher margin expectations and a rebound in international operations, and regulatory pressure on drug pricing could easily challenge both parts of that story.

Another View: Market Multiple Sends A Different Signal

That fair value story sits awkwardly beside the current P/E of 36.9x, which is well above both the US Healthcare sector on 24.3x and a fair ratio of 33.5x. In simple terms, the market is already paying a premium. Is that a cushion or a cliff if expectations shift?

To see how that premium lines up with earnings quality, debt levels, and analyst assumptions, take a closer look at See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With sentiment clearly split between upside potential and richer pricing, this is the moment to look at the underlying data yourself and move quickly. To weigh these trade offs directly, start by reviewing the 4 key rewards and 2 important warning signs.

Ready to act on your next idea?

If Cencora has sharpened your thinking, do not stop here. Put that momentum to work by scanning fresh ideas tailored to different investing goals.

• Target potential mispricing across the market and see which companies stand out on value by running the 54 high quality undervalued stocks.
• Strengthen the income side of your portfolio by focusing on companies that meet a higher yield hurdle with the 12 dividend fortresses.
• Reduce portfolio anxiety by zeroing in on companies that score well on resilience using the 72 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.